MARATTO

article · Cureus

Cost-Effectiveness of S-Adenosyl-L-Methionine for Intrahepatic Cholestasis in the United Arab Emirates

2025Open accessAlexandria University

Abstract

SAMe demonstrates cost-effectiveness compared to UDCA and no treatment for chronic IHC in the UAE, particularly when considering its broader impact on comorbidities. These findings support the integration of SAMe into treatment protocols for IHC, potentially improving patient outcomes and optimizing healthcare resource allocation. Further research is needed to address data gaps, especially regarding UDCA's effects on jaundice and depressed mood in IHC.

Research topics

  • Liver Disease Diagnosis and Treatment
  • Pediatric Hepatobiliary Diseases and Treatments
  • Drug Transport and Resistance Mechanisms

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.7759/cureus.86124

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.